Background-Cardiac myosin-binding protein C (cMyBP-C) is a sarcomeric protein that dynamically regulates thick-filament structure and function. In constitutive cMyBP-C knockout (cMyBP-C Ϫ/Ϫ ) mice, loss of cMyBP-C has been linked to left ventricular dilation, cardiac hypertrophy, and systolic and diastolic dysfunction, although the pathogenesis of these phenotypes remains unclear. Methods and Results-We generated cMyBP-C conditional knockout (cMyBP-C-cKO) mice expressing floxed cMyBP-C alleles and a tamoxifen-inducible Cre-recombinase fused to 2 mutated estrogen receptors to study the onset and progression of structural and functional phenotypes caused by the loss of cMyBP-C. In adult cMyBP-C-cKO mice, knockdown of cMyBP-C over a 2-month period resulted in a corresponding impairment of diastolic function and a concomitant abbreviation of systolic ejection, although contractile function was largely preserved. No significant changes in cardiac structure or morphology were immediately evident; however, mild hypertrophy developed after near-complete knockdown of cMyBP-C. In response to pressure overload induced by transaortic constriction, cMyBP-C-cKO mice treated with tamoxifen also developed greater cardiac hypertrophy, left ventricular dilation, and reduced contractile function. Conclusions-These results indicate that myocardial dysfunction is largely caused by the removal of cMyBP-C and occurs before the onset of cytoarchitectural remodeling in tamoxifen-treated cMyBP-C-cKO myocardium. Moreover, near ablation of cMyBP-C in adult myocardium primarily leads to the development of hypertrophic cardiomyopathy in contrast to the dilated phenotype evident in cMyBP-C Ϫ/Ϫ mice, which highlights the importance of additional factors such as loading stress in determining the expression and progression of cMyBP-C-associated cardiomyopathy. (Circulation. 2012;126:1194-1205.)
H ypertrophic cardiomyopathy (HCM) is an autosomal dominant disease of the myocardium characterized by left ventricular (LV) hypertrophy, myocyte disarray, interstitial fibrosis, and diastolic dysfunction in the absence of known precipitating factors (eg, hypertension, aortic stenosis). In addition to being the leading cause of sudden cardiac death in young athletes, 1 HCM is among the most common genetic diseases of the heart, affecting Ϸ1 in 500 people. 2 Consequently, systematic investigations into the pathogenesis and pathophysiology of HCM are of clinical importance, particularly because phenotypic expression of HCM can lead to significant morbidity and mortality in a wide range of patient age groups. 3, 4 
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Among the most common targets of HCM mutations are the gene that encodes the cardiac isoform of myosin-binding protein C (cMyBP-C), 5, 6 a thick-filament accessory protein found in the A bands in myocardial sarcomeres. Unlike other HCM-associated genes, the majority of cMyBP-C gene mutations are predicted to encode truncated proteins that lack various C-terminal-binding domains 7 involved in targeting cMyBP-C to the thick filament. 8 Consequently, truncation mutants of cMyBP-C are likely unable to incorporate properly into the sarcomere 9 and are rapidly degraded by the ubiquitin-proteasome system of the cell. 10 Consistent with this idea, detectable levels of truncated cMyBP-C have yet to be reported in human myectomy samples harboring heterozygous truncation mutations, [11] [12] [13] although several studies have reported a reduction in the levels of endogenous cMyBP-C. 11, 13 These findings lend credence to the hypothesis that cMyBP-C insufficiency contributes to the pathogenesis of HCM. Accordingly, greater losses of cMyBP-C may account for the enhanced phenotypes observed in patients harboring homozy-gous 14 or compound heterozygous cMyBP-C gene mutations, 15 as well as the clinical finding that a subset of patients with HCM also later develop LV dilation and systolic dysfunction pathognomonic for dilated cardiomyopathy (DCM), 14, 16 otherwise known as burnt-out phase HCM, end-stage HCM, or HCM-associated dilation. Still other patients with cMyBP-C gene mutations bypass the clinical expression of HCM altogether and are initially diagnosed as having DCM. 17, 18 The mechanisms whereby loss of cMyBP-C results in the clinical expression of HCM, HCMassociated dilation, or DCM, however, remain to be elucidated and require further understanding of the roles of cMyBP-C in regulating cardiac structure and function in vivo.
Over the past decade, several unique mouse models have been generated to determine whether elimination of the expression of cMyBP-C (cMyBP-C Ϫ/Ϫ ) 19, 20 or expression of very low amounts of truncated cMyBP-C (cMyBP-C t/t ) 21 is sufficient to cause cardiomyopathies and how the loss of cMyBP-C leads to the pathophysiology of these diseases. Initial studies in cMyBP-C Ϫ/Ϫ 19, 20 and cMyBP-C t/t 21 mice have demonstrated marked LV dilation, myocardial hypertrophy, impaired relaxation, and depressed systolic contractility, which leads to the conclusion that complete or near-complete loss of cMyBP-C is sufficient to cause the development of HCM-associated dilation 19, 20 or DCM. 21 Mechanical measurements on cMyBP-C Ϫ/Ϫ skinned myocardium have also demonstrated changes in contractility at the sarcomeric level, [22] [23] [24] which raises the possibility that functional derangements associated with removal of cMyBP-C underlie the development of cardiac dysfunction in cMyBP-C Ϫ/Ϫ and cMyBP-C t/t mice. A critical gap, however, exists with respect to our understanding of the extent to which loss of cMyBP-C directly contributes to the pathogenesis of cardiac dysfunction. Because characterization studies of cMyBP-C Ϫ/Ϫ and cMyBP-C t/t mice hitherto have largely elucidated the end-stage phenotypes of cMyBP-C ablation, relatively little is known regarding the early changes that occur specifically in response to loss of cMyBP-C. Thus, it is unclear whether functional phenotypes in these mice reflect primary responses of the heart caused by removal of cMyBP-C or secondary responses of the heart caused by activation of compensatory mechanisms after the removal of cMyBP-C. Given the prominent effects of constitutive cMyBP-C ablation (or near ablation) on LV architecture and geometry, it is important to determine whether the direct loss of cMyBP-C predominately mediates the functional derangements observed in cMyBP-C Ϫ/Ϫ and cMyBP-C t/t mice or whether the development of cardiac hypertrophy and LV dilation drives the expression of diastolic 25 and systolic dysfunction. 26 In the present study, we developed a tamoxifen-inducible cMyBP-C conditional knockout (cMyBP-C-cKO) mouse model using Cre/loxP technology to dissociate the primary effects of removing cMyBP-C from the secondary effects of cardiac hypertrophy and LV dilation on cardiac function in vivo. Because cardiac dysfunction had previously been reported to precede the onset of LV remodeling in other mouse models of HCM, 27, 28 we hypothesized that conditional knockdown of cMyBP-C would allow us to isolate the early consequences of removing cMyBP-C before the development of compensatory remodeling, thereby enabling us to unequivocally determine the functional roles of cMyBP-C in the intact heart. Using transthoracic echocardiography, we studied the onset and progression of structural and functional phenotypes caused by the near-complete knockout of cMyBP-C in adult tamoxifen-treated cMyBP-C-cKO mice and compared these findings with age-matched cMyBP-C Ϫ/Ϫ mice previously generated in our laboratory. 19 Adult cMyBP-C-cKO mice treated with tamoxifen were also subjected to mechanical pressure overload induced by transaortic constriction (TAC) to determine the consequences of removing cMyBP-C in the context of hemodynamic stress.
Methods
A detailed description of the materials and methods used in the present study can be found in the online-only Data Supplement.
Experimental Animals
The strategy of Liu et al 29 
Knockdown of cMyBP-C
Tamoxifen (40 mg/kg; Sigma-Aldrich) was administered to 12-week-old cMyBP-C-cKO mice of either sex by intraperitoneal injection for 7 days to induce knockdown of cMyBP-C. Hearts from tamoxifen-and vehicle-treated cMyBP-C-cKO mice were collected subsequently at 2-week intervals to determine the extent of cMyBP-C knockdown.
Protein Analysis
Myofibrillar proteins were isolated from frozen ventricles, separated via SDS-PAGE, and visualized with silver staining. Western blotting was performed with primary antibodies to cMyBP-C (1:2000) and ␤-actin (1:400) and secondary antibodies conjugated to Alexa Fluor 488 and Alexa Fluor 647 (Invitrogen), respectively.
RNA Analysis
Total RNA was isolated from frozen ventricles with TRIzol reagent (Invitrogen). Reverse transcription of total RNA was performed with oligo-d(T) primers and Superscript Reverse Transcriptase III (Invitrogen) to generate total cDNA. Gene expression was assessed with commercial TaqMan assays (Applied Bio-Systems) for atrial natriuretic peptide (Nppa), brain natriuretic peptide (Nppb), ␤-myosin heavy chain (Myh7), and ␤-actin (Actb) and analyzed according to the ⌬⌬C T method.
Histology and Immunohistochemistry
Explanted hearts were fixed with 10% neutral buffered formalin, embedded in paraffin wax, sectioned at 5 m in the coronal plane, and stained with either hematoxylin and eosin or Masson's trichrome. Immunohistochemical labeling of cMyBP-C was performed with polyclonal antibodies against cMyBP-C (1:400 dilution) and secondary antibodies conjugated to Alexa 647 (Invitrogen).
In Vivo Analysis
Transthoracic echocardiography was performed on anesthetized mice as described previously 32 with a Vevo770 high-resolution imaging system (VisualSonics) equipped with a 30-MHz transducer at 2-or 4-week intervals. TAC was performed on anesthetized mice as described previously. 32 
Statistical Analysis
All data are presented as meanϮSEM. Statistical analyses were performed by 2-way ANOVA followed by the Holm-Sidak method for multiple comparisons versus wild-type (WT) controls at baseline (time: Ϫ1 week). For data collected serially with the same experimental animals, statistical analyses were performed with 2-way repeated-measures ANOVA followed by the Holm-Sidak method for multiple comparisons versus WT controls at baseline. Normality was confirmed with the Shapiro-Wilk test. A value of PϽ0.05 was considered significant. Figure 1A illustrates the conditional gene-targeting strategy we used to introduce loxP sites and an FRT-flanked NEO selection cassette into Mybp3. This strategy was designed to induce a frameshift mutation and a premature stop codon after tamoxifen-dependent site-specific recombination of exons 3 to 5, which led to the generation of a Mybp3 null allele. After electroporation of the conditional gene-targeting vector into SV/129 R1 ES (embryonic stem) cells, 33 Southern blot analysis ( Figure 1B ) identified 37 clones that underwent homologous recombination at the 5Ј and 3Ј ends, detected by the appearance of a 2.4-and 7.5-kb EcoRI band, respectively. Of these, 5 clones were karyotyped to confirm normal chromosome complement, 2 of which were microinjected into C57BL/6 blastocysts to produce highly chimeric founders. Subsequent mating of male chimeras with C57BL/6 females produced black and agouti F1 generation mice, the latter of which were genotyped to identify germline transmission of the targeted Mybp3 allele. Figure 1C shows the polymerase chain reaction genotyping strategy used to generate cMyBP-C-cKO mice (Mybp3 
Results

Generation of Tamoxifen-Inducible cMyBP-C-cKO Mice
Conditional Knockdown of cMyBP-C in Adult Murine Myocardium
cMyBP-C-cKO mice were injected with tamoxifen to activate MerCreMer recombinase activity to induce knockdown of cMyBP-C. Figure 2A shows a representative agarose gel demonstrating tamoxifen-dependent site-specific recombination of exons 3 to 5 from the floxed Mybp3 transgene. In the absence of tamoxifen, a single Ϸ1-kb polymerase chain reaction product corresponding to the unrecombined floxed Mybp3 transgene was amplified from cMyBP-C-cKO myocardium treated with vehicle only, which indicates little or no leakage of MerCreMer activity. In contrast, a prominent Ϸ200-bp polymerase chain reaction product was amplified from tamoxifen-treated cMyBP-C-cKO myocardium corresponding to the removal of exons 3 to 5. Consistent with previously published studies, 31 a faint Ϸ1-kb band was still detected in tamoxifen-treated cMyBP-C-cKO myocardium.
To assess the expression of cMyBP-C at the myofilament level after tamoxifen-dependent activation of MerCreMer activity in cMyBP-cKO mice, standard SDS-PAGE and Western blot techniques were used to quantify the loss of cMyBP-C. Figure  2C shows a representative silver-stained SDS-PAGE gel of myofibrillar proteins isolated from WT, cMyBP-C Ϫ/Ϫ , and cMyBP-C-cKO myocardium treated with either vehicle or tamoxifen. cMyBP-C expression in noninduced cMyBP-C-cKO myocardium did not differ significantly from WT myocardium, in agreement with the tamoxifen-dependent activity of MerCreMer recombinase shown in Figure 2A . In contrast, cMyBP-C levels in cMyBP-C-cKO myocardium decreased Ϸ50% in the first 2 weeks after tamoxifen treatment and continued to decline thereafter until Ͻ10% of total cMyBP-C remained after 8 weeks postinduction. This was confirmed by Western blot analysis ( Figure 2C ) and fluorescent immunohistochemical labeling of cMyBP-C in cardiac tissue sections collected 8 weeks after tamoxifen treatment, which demonstrates near-complete knockdown of cMyBP-C in tamoxifen-treated cMyBP-C-cKO myocardium ( Figure 2B ). No detectable levels of cMyBP-C were observed in cMyBP-C Ϫ/Ϫ myocardium by either SDS-PAGE ( Figure 2C ), Western blot ( Figure 2C ), or immunohistochemistry ( Figure 2B ), as previously published. 19 
LV Function in Response to Loss of cMyBP-C in Adult cMyBP-C-cKO Mice
To assess the early changes in cardiac function that occur in vivo after the removal of cMyBP-C, serial transthoracic echocardiograms were collected in cMyBP-C-cKO mice before and after tamoxifen treatment and compared with age-matched WT, cMyBP-C Ϫ/Ϫ , vehicle-treated cMyBP-C-cKO, and tamoxifentreated Mybp3 fl/fl and ␣-MyHC-MerCreMer ϩ/Ϫ controls. Summary data for all echocardiographic measurements are listed in online-only Data Supplement Tables I through V. Before tamoxifen administration (tϭϪ1 week), LV function in cMyBP-CcKO mice was not statistically different from WT mice. Importantly, heart rates and body weights were not significantly different among the genotypes studied. Consistent with previously published results, 19, 32 ejection time (ET; Figure 3A ) and endocardial fractional shortening (EnFS; Figure 4 ) were significantly reduced in cMyBP-C Ϫ/Ϫ mice compared with WT mice, whereas isovolumic relaxation time (IVRT; Figure 3B ) was significantly longer.
In tamoxifen-treated cMyBP-C-cKO mice, ET shortened concurrent with the loss of cMyBP-C ( Figure 3A ). This abbreviation of ET became progressively shorter until after 8 weeks, when little or no cMyBP-C remained in the sarcomere. In a similar manner, IVRT increased concomitantly in cMyBP-C-cKO mice after tamoxifen treatment ( Figure 3B 
Loss of cMyBP-C in Adult Murine Myocardium and Cardiac Remodeling
To study the development and progression of structural and morphological phenotypes caused by the loss of cMyBP-C, gross and histological analyses were performed on formalinfixed hearts obtained from tamoxifen-treated cMyBP-C-cKO mice ( Figure 5 ). Interestingly, despite near-complete ablation of cMyBP-C, no significant difference in gross cardiac morphology was evident 8 weeks after tamoxifen treatment in cMyBP-C-cKO mice compared with WT mice. Consistent with these results, ventricle weight-to-body weight ratios were not statistically different among WT and cMyBP-CcKO mice treated with either vehicle or tamoxifen up to 8 weeks after treatment ( Figure 6A) . However, by 20 weeks after induction, myocyte hypertrophy was discernible via histology ( Figure 5) , and a significant increase in ventricle weight-to-body weight ratio was measured in tamoxifentreated cMyBP-C-cKO mice ( Figure 6A ). In addition, histopathological analysis of cardiac tissue sections stained with Masson's trichrome revealed a slightly increased incidence of focal and diffuse interstitial fibrosis in cMyBP-C-cKO myocardium 20 weeks after tamoxifen treatment ( Figure 5 ), although the extent and location of fibrosis were highly variable. In contrast to WT and cMyBP-C-cKO mice, cMyBP-C Ϫ/Ϫ mice demonstrated marked dilation of the LV, which resulted in a globular morphology on gross examination ( Figure 5 ). Moreover, coronal sections of cMyBP-C Ϫ/Ϫ hearts stained with hematoxylin and eosin demonstrated LV hypertrophy and chamber dilation, whereas staining with Masson's trichrome showed similar areas of diffuse and focal interstitial fibrosis in agreement with previous results. 19 Changes in cardiac structure after the removal of cMyBP-C in tamoxifen-treated cMyBP-C-cKO mice were also assessed via M-mode echocardiography to measure and quantify differences in LV chamber and wall dimensions. Consistent with morphometric data presented above, no statistically significant differences in LV posterior wall thickness in diastole or LV internal dimension in diastole were measured in tamoxifen-treated cMyBP-C-cKO mice up to 8 weeks after induction compared with WT mice ( Figure 3C and 3D) ; however, LV posterior wall thickness in diastole was significantly greater after 20 weeks in tamoxifen-treated cMyBP-C-cKO mice ( Figure 3C ). Interestingly, no significant changes in LV internal dimension in diastole were measured in tamoxifen-treated cMyBP-C-cKO mice 20 weeks after tamoxifen treatment ( Figure 3D ). In contrast, LV internal dimension in diastole and LV posterior wall thickness in diastole were significantly increased in cMyBP-C Ϫ/Ϫ mice at all time points, in agreement with previous results. 19, 32 
Molecular Markers of Hypertrophy in Tamoxifen-Treated cMyBP-C-cKO Myocardium
To determine whether the expression of hypertrophy-associated genes in tamoxifen-treated cMyBP-C-cKO myocardium was evident even in the absence of cardiac hypertrophy 8 weeks after tamoxifen induction, mRNA levels of Nppa, Nppb, and Myh7 were quantified by real-time quantitative polymerase chain reaction and compared with WT, cMyBP-C Ϫ/Ϫ , and vehicle-treated cMyBP-C-cKO mice ( Figure 6B ). No significant differences were observed between WT and cMyBP-C-cKO myocardium treated with either vehicle or tamoxifen; however, an increasing trend in the mRNA expression of Nppa and Myh7 was noted in tamoxifentreated cMyBP-C-cKO myocardium. In contrast, Nppa, Nppb, and Myh7 mRNA levels were all dramatically elevated in cMyBP-C Ϫ/Ϫ myocardium, as reported previously. 19 By 20 weeks after tamoxifen induction, however, mRNA levels of Nppa, Nppb, and Myh7 were all statistically elevated in tamoxifen-treated cMyBP-C-cKO mice compared with WT mice, consistent with the initial development of myocardial hypertrophy.
Effects of Pressure Overload in Tamoxifen-Treated cMyBP-C-cKO Mice
To investigate the phenotypic effects of cMyBP-C knockdown in the context of hemodynamic stress, tamoxifen-and vehicle-treated cMyBP-C-cKO mice were subjected to pressure overload induced by TAC for a period of up to 12 weeks. Both tamoxifen-and vehicle-treated cMyBP-C-cKO mice developed LV hypertrophy comparable to that measured in cMyBP-C Ϫ/Ϫ mice after 4 weeks of TAC ( Figure 7A) ; however, LV chamber dilation only developed in tamoxifentreated cMyBP-C-cKO mice after 8 weeks of TAC ( Figure  7B ). With respect to cardiac function, EnFS was largely preserved in vehicle-treated cMyBP-C-cKO mice after TAC ( Figure 7C ). In contrast, EnFS progressively declined in tamoxifen-treated cMyBP-C-cKO mice after TAC until LV performance was comparable to cMyBP-C Ϫ/Ϫ mice after 12 weeks. Importantly, tamoxifen-treated cMyBP-C-cKO mice subjected to TAC also exhibited prolonged IVRT and abbreviated ET compared with WT mice. No statistically significant differences in ET or IVRT were detected in Mybp3 fl/fl or ␣-MyHC-MerCreMer ϩ/Ϫ experimental controls treated with tamoxifen and subjected to TAC compared with WT mice (online-only Data Supplement Figure III) .
With respect to histopathology, cMyBP-C-cKO mice treated with vehicle and tamoxifen both developed myocyte hypertrophy in response to TAC. Likewise, Mybp3 fl/fl and ␣-MyHC-MerCreMer ϩ/Ϫ experimental controls treated with tamoxifen and subjected to TAC also developed myocyte hypertrophy (online-only Data Supplement Figure IV) . However, only tamoxifen-treated cMyBP-C-cKO mice developed myocyte disarray and myocardial fibrosis 12 weeks after TAC.
Discussion
In the present study, we developed a cMyBP-C-cKO mouse model expressing floxed Mybp3 alleles and a tamoxifendependent MerCreMer recombinase under the transcriptional control of the ␣-MyHC promoter. 31 Using a conditional knockout approach to acutely terminate the expression of cMyBP-C in adult myocardium, we determined and interrelated the time course of cMyBP-C knockdown with the onset and development of structural and functional phenotypes, thereby allowing us to differentiate the primary effects of removing cMyBP-C from the secondary effects of compensatory mechanisms (eg, ventricular remodeling) on cardiac function in vivo. On the basis of gross morphometric, histological, and echocardiographic data, we found that cardiac dysfunction preceded the development of LV hypertrophy in cMyBP-C-cKO mice after the removal of cMyBP-C. More specifically, loss of cMyBP-C resulted in concurrent shortening of ET and prolongation of IVRT before the onset of cardiac remodeling that was commensurate with the degree of cMyBP-C knockdown, which implies a prominent role for cMyBP-C in regulation of the period of cardiac systole and diastole. Interestingly, subsequent development of LV hypertrophy after near-complete ablation of cMyBP-C in cMyBP-C-cKO mice did not have an additional effect on ET, whereas IVRT continued to increase in parallel with the development of cardiac hypertrophy. These results indicate that truncation of ET and prolongation of IVRT in cMyBP-C-deficient mice occurs primarily in response to the removal of cMyBP-C, although IVRT increases further in response to LV hypertrophy.
Our finding that cardiac dysfunction preceded the onset of cardiac remodeling in the present study is consistent with other mouse models of HCM that harbor either ␣-MyHC 27 or cardiac troponin T mutations. 28 Interestingly, this dissociation of structural and functional phenotypes in response to the removal of cMyBP-C in cMyBP-C-cKO mice continued until cMyBP-C knockout was nearly complete, which indicates that adult murine myocardium tolerates considerable reductions in the expression of cMyBP-C without immediately undergoing significant cardiac remodeling. Despite near-complete ablation of cMyBP-C in tamoxifen-treated cMyBP-C-cKO mice, however, only mild cardiac hypertrophy developed, in contrast to the marked LV hypertrophy and chamber dilation present in cMyBP-C Ϫ/Ϫ 19,20 and cMyBP-C t/t mice. 21 Moreover, near ablation of cMyBP-C in tamoxifen-treated cMyBP-C-cKO mice did not recapitulate the severe systolic dysfunction previously demonstrated in cMyBP-C Ϫ/Ϫ 19, 20, 32 and cMyBP-C t/t mice, 21 ie, EnFS was largely preserved in tamoxifen-treated cMyBP-C-cKO even when Ͻ10% of total cMyBP-C remained. This apparent lack of effect of cMyBP-C knockdown on EnFS is perhaps surprising given the significant shortening of ET in these mice, which in turn might be predicted to limit EnFS. A concomitant acceleration of contraction kinetics caused by the loss of cMyBP-C, however, could potentially account for the preservation of EnFS in tamoxifen-treated cMyBP-C- cKO mice. Indeed, considerable evidence from mechanical measurements performed in cMyBP-C Ϫ/Ϫ skinned myocardium suggests that cross-bridge cycling kinetics are accelerated in the absence of cMyBP-C, 22, 23 which would in turn speed the rate of pressure development in the intact heart. Thus, loss of systolic contractile function in cMyBP-C Ϫ/Ϫ and cMyBP-C t/t mice most likely involves modifying factors activated subsequent to the ablation of cMyBP-C. Together, these results demonstrate that acute loss of cMyBP-C in adult mice per se is insufficient to cause the expression of DCM or HCM-associated dilation previously reported in cMyBP-C t/t21
and cMyBP-C Ϫ/Ϫ mice, 19, 20 respectively. To investigate whether additional stressors could induce the expression of HCM-associated dilation in tamoxifentreated cMyBP-C-cKO mice, TAC was introduced to increase hemodynamic workload. Interestingly, loss of systolic contractile function was precipitated in tamoxifen-treated cMyBP-C-cKO mice subjected to TAC. In addition, these mice developed progressive LV chamber dilation and further hypertrophy of the LV wall, recapitulating the dilated HCM phenotype previously reported in cMyBP-C Ϫ/Ϫ mice. 19, 20 Importantly, these phenotypes were largely absent in vehicletreated cMyBP-C-cKO mice subjected to TAC (with the exception of hypertrophy). Together, these results indicate that both knockout of cMyBP-C and additional precipitating factors are needed to drive the expression of HCM-associated dilation in tamoxifen-treated cMyBP-C-cKO mice. Consistent with this idea, loss of systolic contractile function in tamoxifen-treated cMyBP-C-cKO mice subjected to TAC was not statistically significant until knockout of cMyBP-C was nearly complete. Interestingly, this effect of cMyBP-C knockdown on contractile function in tamoxifen-treated cMyBP-C-cKO mice coincided with the development of LV dilation, which suggests that increases in LV chamber dilation may exacerbate the functional effects of cMyBP-C ablation on systolic function. Indeed, increases in the diameter of the LV would be expected to increase wall stress according to the law of LaPlace, which could in turn limit EnFS. 26 Although increased afterload induced by TAC might also be expected to diminish EnFS, this consideration is not applicable in cMyBP-C Ϫ/Ϫ mice, because hemodynamic load in these mice is not significantly different from WT mice. Taken together, these results suggest that the development of LV dilation in cMyBP-C Ϫ/Ϫ mice contributes to the pathogenesis of depressed cardiac function (beyond effects caused by ablation of cMyBP-C).
The mechanisms underlying the development of LV dilation in cMyBP-C Ϫ/Ϫ and cMyBP-C t/t mice, however, remain largely unknown. Previous studies have suggested a genedosage effect, 19 -21,34 because cMyBP-C ϩ/Ϫ and cMyBP-C t/ϩ mice exhibited milder or unaltered phenotypes compared with their respective homozygous counterparts. Results presented in this study suggest that additional disease-modifying factors are required to precipitate the expression of HCMassociated dilation or DCM, because near-to-complete loss of cMyBP-C in adult murine myocardium was insufficient to cause ventricular dilation and systolic dysfunction per se. An important difference between the cMyBP-C-cKO mice in the present study and the cMyBP-C Ϫ/Ϫ and cMyBP-C t/t mice of previous studies was the timing of cMyBP-C knockout, ie, adult versus embryonic knockout. This distinction may provide valuable insights into potential mechanisms underlying the development of LV dilation and systolic dysfunction in cMyBP-C Ϫ/Ϫ and cMyBP-C t/t mice versus the development of HCM in cMyBP-C-cKO mice. There are several fundamental differences between mature myocardium and developing myocardium in utero, which in turn may modulate the effects that loss of cMyBP-C may have on cardiac structure and function. For example, the predominant isoform of MyHC expressed during murine cardiac development is ␤-MyHC, which later switches to the ␣-MyHC isoform during early neonatal development and becomes the predominant isoform in adult myocardium. 35 Replacement of ␣-MyHC with predominantly ␤-MyHC in cMyBP-C t/t mice 36 previously has been shown to exacerbate the expression of the morphological phenotype associated with cMyBP-C t/t mice, 21 which suggests that the functional effects of removing cMyBP-C are more severe on a ␤-MyHC background than a predominantly ␣-MyHC background. There is increasing evidence to suggest that the introduction of HCM mutations onto an ␣-MyHC or ␤-MyHC background may have disparate effects on contractile function. 37 Indeed, the slower turnover kinetics of ␤-MyHC 38 could result in a greater reduction in peak twitch force production after ablation of cMyBP-C. These studies raise the possibility in mice that loss of cMyBP-C requires a predominantly ␤-MyHC background (at least initially) to lead to the development of HCMassociated dilation or DCM. Along this same line of reasoning, expression of the ␣-MyHC isoform may be cardioprotective with respect to the deleterious functional effects of removing cMyBP-C in murine myocardium.
In summary, tamoxifen-induced loss of cMyBP-C in cMyBP-C-cKO mice causes functional derangements in ET and IVRT that occur before the onset of compensatory cardiac remodeling, which supports the idea that cMyBP-C plays important roles in regulating normal systolic and diastolic function. In addition, we provide novel evidence suggesting that LV dilation may contribute to the depression in cardiac function previously demonstrated in cMyBP-C Ϫ/Ϫ 19,20 and cMyBP-C t/t 21 mice, whereas LV hypertrophy only contributes to the prolongation of IVRT. These results underscore the role of additional factors or stressors in governing the clinical expression of cMyBP-C-associated cardiomyopathy and predict the clinical utility of interventions that prevent or delay the onset of cardiac remodeling or reverse the progression of LV hypertrophy to LV chamber dilation.
